CAR‑T Cell Monitoring Using Multiparametric Flow Cytometry in Patients with B Cell Malignancies (ICBMT 2026) - Oct 8, 2026 - Abstract #PP08‑04; "Our findings suggest that flow cytometric immune monitoring can provide clinically relevant information beyond CAR‑T quantification by simultaneously characterizing CAR‑T expansion, endogenous immune phenotypes, and immune features associated with treatment‑related toxicity. Keywords : Chimeric Antigen Receptor T‑cell (CAR‑T), Tisagenlecleucel, Multiparameter Flow Cytometry (MFC), Diffuse Large B‑cell Lymphoma (DLBCL), B‑cell Precursor Acute Lymphoblastic Leukemia (B‑ALL)"
CAR T-Cell Therapy • Clinical • IO biomarker • Acute Lymphocytic Leukemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • CD4 • CD8 • TIGIT
|
|
Sungyu Jee 1; Taewon Kang 2; Hyunjoo Bae 2; Takho Kang 1; Jin Jung 1; Yonggoo Kim 1; Myungshin Kim 1; Jae‑Won Yoo 3; Gi June Min 4; Dong Wook Jekarl 1; Jong‑Mi Lee 1
|